Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
德琪(浙江)医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021
2021-06-02 08:00
Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021
2021-06-02 08:00
Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome
2021-05-28 08:00
Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development
2021-05-25 08:00
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)
2021-05-17 20:35
Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial
2021-05-17 08:00
Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China
2021-05-14 08:40
Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies
2021-05-14 08:00
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
2021-05-13 08:00
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
2021-05-06 11:28
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
2021-04-29 08:34
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL
2021-04-13 08:00
Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations
2021-04-12 08:00
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
2021-04-06 08:00
Antengene Announces Financial Results for Full Year 2020
2021-03-26 08:00
Antengene Appoints Kevin Lynch as Chief Medical Officer
2021-03-25 23:26
Antengene Appoints Bo Shan as Chief Scientific Officer
2021-03-25 22:36
Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021
2021-03-22 08:00
Antengene Included in the Shenzhen-Hong Kong Stock Connect
2021-03-15 09:40
Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea
2021-03-15 08:00
1
4
5
6
7
8